Aditya H Gaur, Edmund V Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Cynthia McCoig, Rodica M Van Solingen-Ristea, Sisinyana Ruth Mathiba, Adeola Adeyeye, John H Moye, Barbara Heckman, Elizabeth D Lowenthal, Shawn Ward, Ryan Milligan, Pearl Samson, Brookie M Best, Conn M Harrington, Susan L Ford, Jenny Huang, Herta Crauwels, Kati Vandermeulen, Allison L Agwu, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Pradthana Ounchanum, Jared L Kneebone, Ellen Townley, Carolyn Bolton Moore
BACKGROUND: Combined intramuscular long-acting cabotegravir and long-acting rilpivirine constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for adults with HIV. The goal of the IMPAACT 2017 study (MOCHA [More Options for Children and Adolescents]) was to assess the safety and pharmacokinetics of these drugs in adolescents. METHODS: In this phase 1/2, multicentre, open-label, non-comparative, dose-finding study, virologically suppressed adolescents (aged 12-17 years; weight ≥35 kg; BMI ≤31·5 kg/m2 ) with HIV-1 on daily oral ART were enrolled at 15 centres in four countries (Botswana, South Africa, Thailand, and the USA)...
April 2024: Lancet HIV